Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity

• Published in: Clinical cancer research Vol. 27; no. 2; pp. 542 - 553
• Main Authors: Hong, Bangxing, Chapa, Valerie, Saini, Uksha, Modgil, Puneet, Cohn, David E., He, Guangan, Siddik, Zahid H., Sood, Anil K., Yan, Yuanqing, Selvendiran, Karuppaiyah, Pei, Guangsheng, Zhao, Zhongming, Yoo, Ji Young, Kaur, Balveen
• Format: Journal Article
• Language: English
• Published: United States 15.01.2021
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Cell Line, Tumor; Cells, Cultured; Cisplatin - therapeutic use; Combined Modality Therapy; Disease Models, Animal; DNA Adducts - genetics; DNA Adducts - immunology; Female; Herpesvirus 1, Human - physiology; Humans; Immunotherapy - methods; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Oncolytic Virotherapy - methods; Ovarian Neoplasms - genetics; Ovarian Neoplasms - therapy; Ovarian Neoplasms - virology; Signal Transduction - genetics; Signal Transduction - immunology; Treatment Outcome; Xenograft Model Antitumor Assays - methods

Here we investigated the impact of oncolytic herpes simplex virus (HSV) treatment on cisplatin sensitivity of platinum-resistant ovarian cancer, and the impact of the combination on immunotherapy. Therapeutic efficacy of the combination was assessed in platinum-resistant human and murine ovarian can...